A new window in multiple sclerosis pathology: non-conventional quantitative magnetic resonance imaging outcomes (Q33526913)

27 July 2017

1 reference

title

A new window in multiple sclerosis pathology: non-conventional quantitative magnetic resonance imaging outcomes (English)

1 reference

27 July 2017

0 references

0 references

1

Frauke Zipp

0 references

publication date

1 December 2009

1 reference

Journal of the Neurological Sciences

27 July 2017

published in

1 reference

27 July 2017

volume

287 Suppl 1

1 reference

27 July 2017

page(s)

S24-9

1 reference

CNS-irrelevant T-cells enter the brain, cause blood-brain barrier disruption but no glial pathology.

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Perivascular spaces--MRI marker of inflammatory activity in the brain?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Eight-year follow-up study of brain atrophy in patients with MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Spinal cord imaging in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Magnetization transfer magnetic resonance imaging in the assessment of neurological diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Normalized accurate measurement of longitudinal brain change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

A study of multiple sclerosis patients with magnetic resonance spectroscopic imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Chemical pathology of acute demyelinating lesions and its correlation with disability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

MR spectroscopy in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

Detection of lesions in multiple sclerosis by 2D FLAIR and single-slab 3D FLAIR sequences at 3.0 T: initial results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2971297-3

10.1016/S0022-510X(09)71297-3

7 January 2021

Identifiers

DOI

1 reference

27 July 2017

1 reference